Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the Company was recently invited by one of Great Britain’s leading chains of psychiatric clinics to present EDOR® at a seminar for 90 caregivers in London.

 

181001- Emotra – Newsletter – Important developments for Emotra